Genetic Disorders

Latest News

Patient Dosing Commenced in Phase 1/2 Gene Therapy Trial of Limb-Girdle Muscular Dystrophy Type 2I/R9
Patient Dosing Commenced in Phase 1/2 Gene Therapy Trial of Limb-Girdle Muscular Dystrophy Type 2I/R9

August 7th 2023

The trial is expected to include 14 individuals with genetically confirmed limb-girdle muscular dystrophy who will be randomly assigned 1:1 to either AB-1003 or placebo for a year-long treatment period.

Gene Therapy ST-920 Shows Favorable Impact on Fabry Disease in Phase 1/2 Study
Gene Therapy ST-920 Shows Favorable Impact on Fabry Disease in Phase 1/2 Study

February 27th 2023

Clinician Perspectives on Black History Month: Part 2
Clinician Perspectives on Black History Month: Part 2

February 23rd 2023

Clinician Perspectives on Black History Month: Part 1
Clinician Perspectives on Black History Month: Part 1

February 21st 2023

Clinician Perspectives on Black History Month: Jennifer Adrissi, MD
Clinician Perspectives on Black History Month: Jennifer Adrissi, MD

February 20th 2023

Video Interviews
Podcasts
Angelman syndrome researcher

More News

© 2024 MJH Life Sciences

All rights reserved.